Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Roth Upgrades Ceradyne to Buy

Roth Capital upgraded Ceradyne (CRDN) to buy from hold.

Analyst Steven Gish says the House recently passed the fiscal 2005 (Sep.) National Defense Authorization Act, allocating over $400 million for body armor. He says Ceradyne stands to benefit directly from this funding as it's one of leading providers of small arms protective inserts.

Gish notes new contracts could come down this summer, which would also bode well for the company. In addition, he thinks that Ceradyne's recent acquisition of Quest Technology could benefit its orthopedic segment in the long run. He raised the $1.22 2004 EPS estimate to $1.27, and upped the $1.35 2005 estimate to $1.44. He has a $38 target.

blog comments powered by Disqus